$1.49 +0.11 (7.86%)
Boundless Bio, Inc. Common Stock (BOLD)
Boundless Bio, Inc. (BOLD) is a biotechnology company focused on developing targeted therapies for cancer and other parts of the immune system. The company leverages its proprietary platforms to identify and develop innovative treatments aimed at addressing unmet medical needs.
Company News
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Boundless Bio, a clinical-stage oncology company, reported its Q1 2025 financial results and provided updates on its pipeline. The company has a cash position of $138.3 million, which is expected to fund operations into 2027. Boundless Bio is advancing its BBI-355 program, a CHK1 inhibitor, and its novel Kinesin program, with key milestones expec...